Date Added: 20/03/2017

Date Updated: 20/03/2017

Avelumab for advanced non-small cell lung cancer — first line

Specialties: Oncology & radiotherapy

Technology Type: Drugs

Stage of development: Investigational - phase III

Stage of EAA: Prioritised for assessment

Description, patients and keywords:

Indication

Non-small cell lung cancer (NSCLC).

Subgroup

Programmed death ligand 1 (PD-L1) positive.

Stage of disease

Advanced, metastatic or recurrent disease.

Place in Treatment

First line.

This report is work in progress and should not be used for external distribution without permission from the originating agency. Users should be aware that reports are based on information available at the time of research and often on a limited literature search.